Hovione has unveiled plans for investing in specialized formulation capabilities. The first step of the plan was the acquisition of a formulation facility adjacent to the current process chemistry and particle engineering facility in Loures, Portugal. This acquisition is a strategic investment to further boost development and manufacturing capabilities for both inhalation and oral dosage forms. The facility will be engineered to enable to work with highly potent APIs and moisture sensitive co...